PD-L1 distribution and perspective for cancer immunotherapy—blockade, knockdown, or inhibition
Cancer immunotherapy involves blocking the interactions between the PD-1/PD-L1 immune
checkpoints with antibodies. This has shown unprecedented positive outcomes in clinics …
checkpoints with antibodies. This has shown unprecedented positive outcomes in clinics …
Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway
Tumor cells form immune escape and subsequently obtain unlimited proliferation ability due
to the abnormal immune surveillance mediated by immune checkpoints. Among this class of …
to the abnormal immune surveillance mediated by immune checkpoints. Among this class of …
[HTML][HTML] A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naïve patients with advanced NSCLC
A Lisberg, A Cummings, JW Goldman… - Journal of Thoracic …, 2018 - Elsevier
Background Despite the significant antitumor activity of pembrolizumab in NSCLC, clinical
benefit has been less frequently observed in patients whose tumors harbor EGFR mutations …
benefit has been less frequently observed in patients whose tumors harbor EGFR mutations …
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective …
Purpose: PD-1 inhibitors are established agents in the management of non–small cell lung
cancer (NSCLC); however, only a subset of patients derives clinical benefit. To determine …
cancer (NSCLC); however, only a subset of patients derives clinical benefit. To determine …
Worldwide prevalence of epidermal growth factor receptor mutations in non-small cell lung cancer: a meta-analysis
B Melosky, K Kambartel, M Haentschel… - Molecular Diagnosis & …, 2022 - Springer
Background Identification of variable epidermal growth factor receptor (EGFR) gene
mutations in non-small cell lung cancer (NSCLC) is important for the selection of appropriate …
mutations in non-small cell lung cancer (NSCLC) is important for the selection of appropriate …
Immunotherapy in treating EGFR-mutant lung cancer: current challenges and new strategies
KKW To, W Fong, WCS Cho - Frontiers in Oncology, 2021 - frontiersin.org
Lung cancer is the leading cause of cancer-related deaths worldwide. Immune checkpoint
inhibitors, including monoclonal antibodies against programmed death-1 (PD-1) and …
inhibitors, including monoclonal antibodies against programmed death-1 (PD-1) and …
[HTML][HTML] PD-L1 expression in lung cancer
Immunotherapies targeted against programmed death ligand 1 (PD-L1) and its receptor (PD-
1) have improved survival in a subset of patients with advanced lung cancer. PD-L1 protein …
1) have improved survival in a subset of patients with advanced lung cancer. PD-L1 protein …
Lung cancer staging and prognosis
GA Woodard, KD Jones, DM Jablons - Lung cancer: treatment and …, 2016 - Springer
The seventh edition of the non-small cell lung cancer (NSCLC) TNM staging system was
developed by the International Association for the Staging of Lung Cancer (IASLC) Lung …
developed by the International Association for the Staging of Lung Cancer (IASLC) Lung …
[HTML][HTML] PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review
R Brody, Y Zhang, M Ballas, MK Siddiqui, P Gupta… - Lung cancer, 2017 - Elsevier
Tumors can evade immune detection by exploiting inhibitory immune checkpoints such as
the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathway …
the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathway …
[HTML][HTML] The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer
N Zhang, Y Zeng, W Du, J Zhu… - International …, 2016 - spandidos-publications.com
Negative regulation of the signal mediated by the programmed cell death protein 1 (PD-
1)/programmed death-ligand 1 (PD-L1) pathway can effectively inhibit the function of T and …
1)/programmed death-ligand 1 (PD-L1) pathway can effectively inhibit the function of T and …